Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) has announced the completion of the second tranche of its previously announced unit private placement, raising gross proceeds of $2.5 million. The company issued 6,250,000 units at a price of $0.40 per unit, with each unit consisting of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase an additional common share at an exercise price of $0.50 for a period of three years.
This tranche brings the total gross proceeds raised under the offering to $2,948,130. The overall offering is for up to 8,000,000 units, targeting gross proceeds of up to $3.2 million, with the remaining units expected to be sold in subsequent tranches. The company paid Ventum Financial Corp. cash commissions of $200,000 and issued 500,000 warrants for their assistance in finding subscribers.
The warrants issued in this tranche include an acceleration clause. If the volume weighted average trading price of the common shares on the TSX Venture Exchange is at least $0.75 for 30 consecutive trading days, the corporation may accelerate the expiry date of the warrants to a date not less than 30 days after notice is provided to warrant holders via press release.
The net proceeds from the offering are intended to fund the company's continuing first-in-human clinical trials, ongoing research and development, and general working capital. However, the actual allocation may vary depending on future operations, events, or opportunities.
The closing of this tranche was subject to conditional approval from the TSX Venture Exchange, which was obtained. All common shares and warrants issued are subject to a hold period of four months and one day from the date of issuance, with finder warrants being non-transferable.
Ocumetics is a Canadian research and product development company focused on advanced vision correction solutions. Its flagship technology is a dynamic intraocular lens designed to fit within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses. The lens is intended to use the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without glasses or contact lenses and without perceptible time lag.
The company is currently in the first-in-human early feasibility study phase of this technology, which could transform the ophthalmic industry. The successful completion of this private placement provides the necessary capital to advance these trials, bringing the company closer to potentially offering a revolutionary alternative to traditional corrective lenses.
This financing milestone underscores investor confidence in Ocumetics' vision and the potential impact of its technology on the field of ophthalmology. As the company progresses with its clinical trials, the outcomes will be critical in determining the future of this innovative approach to vision correction.
